Please select the option that best describes you:
How would you treat metastatic colon CA with BRAF non-V600E mutation?
Would you consider the BEACON regimen (i.e., encorafenib/binimetinib + cetuximab) in this setting?
Answer from: Medical Oncologist at Academic Institution
BRAF mutated metastatic colorectal cancer is about 7-10% of all metastatic colorectal cancer. When we discuss BRAF mutated metastatic colorectal cancer, we mainly/only focus on BRAF V600E mutated metastatic colorectal cancer, however, about 22% of BRAF mutations are Non-V600E which means about 2% of...
Sign in or Register to read more